FDA Holds Public Hearing on Psychedelic Drugs Amid Trump Administration Push

The U.S. FDA held a public hearing on Monday to gather feedback on the therapeutic use of psychedelic drugs for serious mental illnesses.

The session follows an April order by President Donald Trump directing the agency to prioritize psychedelic drug programs and collaborate with the DEA.

Doctors, veterans, and therapists urged the regulator during the hearing to establish clear safety standards and mandatory trained staff for future treatments.